Vilanterol trifenatate for the treatment of COPD

Mario Malerba, Alessandro Radaeli, Paolo Montuschi, Jaymin B. Morjaria

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

10 Citazioni (Scopus)


INTRODUCTION: Currently the treatment of chronic obstructive pulmonary disease (COPD) has limited effectiveness and there is a need to develop new drugs. International guidelines recommend the use of long-acting bronchodilators (β2 agonists and anti-cholinergics/muscarinics), inhaled steroids and associations between these drugs in the maintenance treatment of moderate-to-severe COPD. AREA COVERED: Vilanterol trifenate is a new once-daily highly selective β2-agonist available in USA and Europe in association with umeclidinium bromide (a long-acting anti-muscarnic agent) and fluticasone furoate (an inhaled corticosteroid) for the once-daily maintenance treatment of COPD. Vilanterol combined in fixed-dose treatments has been tested in numerous clinical trials involving thousands of patients. Expert commentary: These new once-daily formulations have the potential to improve compliance to long-term inhaled therapy. This paper will review the clinical and experimental data regarding vilanterol use in the regular treatment of COPD as well as provide a critical discussion of possible future treatment settings.
Lingua originaleEnglish
pagine (da-a)719-731
Numero di pagine13
RivistaExpert Review of Respiratory Medicine
Stato di pubblicazionePubblicato - 2016


  • COPD treatment
  • LABA
  • LAMA
  • fluticasone furoate
  • umeclidinium bromide
  • vilanterol trifenate


Entra nei temi di ricerca di 'Vilanterol trifenatate for the treatment of COPD'. Insieme formano una fingerprint unica.

Cita questo